Phoenix Grp.29 (71WZ) News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

U.S. Futures Rise on Fed Decision; Oil Gains on Demand Forecasts

U.S. index futures are trading slightly higher in pre-market on Monday, amidst anticipation of the Fed’s...

Affimed Reports First Quarter 2024 Financial Results & Business Update

- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of...

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort

In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and...

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Annual General Meeting of Shareholders

MANNHEIM, Germany, May 28, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024

In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum...

Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress

Treatment with AFM28 innate cell engager (ICE®), designed to target CD123-positive cancer cells in patients...

Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology

The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor...

Affimed Reports 2023 Financial Results and Operational Progress

AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four...